Lam Research Work in process increased by 10.2% to $388.36M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.3%, from $307.48M to $388.36M. Over 4 years (FY 2021 to FY 2025), Work in process shows a downward trend with a -7.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $391.69M | $431.65M | $385.04M | $454.72M | $471.35M | $515.94M | $384.39M | $396.42M | $325.61M | $300.41M | $225.63M | $290.74M | $284.08M | $337.75M | $357.32M | $307.48M | $282.89M | $315.93M | $352.34M | $388.36M |
| QoQ Change | — | +10.2% | -10.8% | +18.1% | +3.7% | +9.5% | -25.5% | +3.1% | -17.9% | -7.7% | -24.9% | +28.9% | -2.3% | +18.9% | +5.8% | -13.9% | -8.0% | +11.7% | +11.5% | +10.2% |
| YoY Change | — | — | — | — | +20.3% | +19.5% | -0.2% | -12.8% | -30.9% | -41.8% | -41.3% | -26.7% | -12.8% | +12.4% | +58.4% | +5.8% | -0.4% | -6.5% | -1.4% | +26.3% |
| % of Inventories | 14.6% | 15.0% | 12.5% | 13.1% | 11.9% | 11.8% | 8.0% | 8.1% | 6.8% | 6.3% | 5.1% | 6.7% | 6.7% | 8.0% | 8.2% | 6.9% | 6.6% | 7.7% | 8.7% | 9.7% |
| Share Change | — | +0.5pp | -2.5pp | +0.5pp | -1.2pp | -0.1pp | -3.9pp | +0.1pp | -1.4pp | -0.4pp | -1.2pp | +1.6pp | +0.0pp | +1.3pp | +0.2pp | -1.3pp | -0.3pp | +1.1pp | +1.0pp | +1.0pp |